We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
- Authors
Kieran, Mark W; Packer, Roger J; Onar, Arzu; Blaney, Susan M; Phillips, Peter; Pollack, Ian F; Geyer, J Russell; Gururangan, Sri; Banerjee, Anu; Goldman, Stewart; Turner, Christopher D; Belasco, Jean B; Broniscer, Alberto; Zhu, Yali; Frank, Emily; Kirschmeier, Paul; Statkevich, Paul; Yver, Antoine; Boyett, James M; Kun, Larry E
- Abstract
A dose-escalation phase I and pharmacokinetic study of the farnesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors. Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Vol 25, Issue 21, p3137
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2006.09.4243